The JPEO-CBRND has awarded a contract worth up to $20.8 million to the biotechnology company Inflammatix for purchase of their TriVerity™ test system for military use. An initial $1.2 million has already been awarded to cover the first phase of system evaluation. This agreement comes at a time of increasing risk of acute infection and sepsis in the U.S. military, highlighting the need for a portable, well-built diagnostic test that can rapidly and reliably detect the presence and assess the severity of infection under battlefield conditions.

Link to full company press release here: https://inflammatix.com/inflammatix-ships-triverity-myrna-instruments-to-us-military/